Expert Discusses CMB305 Immunotherapy Regimen in Sarcoma – OncLive
OncLive |
Expert Discusses CMB305 Immunotherapy Regimen in Sarcoma
OncLive Results presented at the 2017 ASCO Annual Meeting showed that CMB305, an immunotherapy regimen that generates and expands anti–NY-ESO-1 T cells, demonstrated a favorable survival rate compared with other approved agents for recurrent soft tissue … |
